Abstract
Postoperative hemorrhage remains a significant cause of mortality and morbidity after repair of acute aortic dissection. Accordingly, there has been great interest in the development and application of biologic hemostatic tissue sealants for use during this and other aortic surgical procedures. Among these agents, BioGlue (Cryolife, Inc, Kennesaw, Ga) appears remarkably effective and has rapidly gained wide acceptance. However, because it is composed of 45% (wt/vol) purified bovine albumin and 10% (wt/vol) glutaraldehyde in a 4:1 ratio, we have been concerned that it might not be completely innocuous. We have recently encountered a case of late anastomotic pseudoaneurysm potentially related to the use of BioGlue.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Thoracic and Cardiovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
